WallStSmart
REVB

Revelation Biosciences Inc

NASDAQ: REVB · HEALTHCARE · BIOTECHNOLOGY

$1.04
-6.16% today

Updated 2026-06-05

Market cap
$3.99M
P/E ratio
P/S ratio
2.88x
EPS (TTM)
$-1.32
Dividend yield
52W range
$1 – $13
Volume
0.1M

Revelation Biosciences Inc (REVB) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201420152016201720182019202020212022202320242025
Operating cash flow$11.60M$11.60M$24.25M$32.58M$41.09M$-215074.00$-11.09M$-11.22M$-7.29M$-18.32M$-8.27M
Capital expenditures$0.00$582000.00$582000.00$804000.00$861000.00$526000.00$4.00$131963.00$4.00$4.00$19171.00$0.00
Depreciation
Stock-based comp$43848.00$470878.00$301116.00$155721.00$168850.00$595368.00
Free cash flow$11.02M$11.02M$23.44M$31.72M$40.56M$-215078.00$-11.22M$-11.22M$-7.29M$-18.34M$-8.27M
Investing cash flow
Financing cash flow
Dividends paid$7.65M$5.95B
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does REVB generate?

REVB produced $-8.27M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is REVB's balance sheet healthy?

REVB holds $10.70M in cash and equivalents against — in long-term debt, on $8.86M of shareholder equity. That debt is best read against the cash flow the business throws off each year.